Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal cancer

Published Date: 29 Jan 2025

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot